1-20 of 553 Search Results for

cvd-cardiovascular-disease

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Meeting Abstracts
Journal: Diabetes
Diabetes 2020;69(Supplement_1):251-OR
Published: 01 June 2020
...GIOVANE R. SOUSA, SR.; MONIKA NIEWCZAS; MYRA A. LIPES CVD is the leading cause of mortality in T1D; however, only ∼50% of this risk is explained by traditional risk factors. Recent studies show that subjects with T1D in the DCCT developed cardiac autoimmunity, defined by the presence of ≥2 Ab. We...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):88-OR
Published: 01 June 2019
...TINA COSTACOU; AMY K. SAENGER; TREVOR J. ORCHARD High-sensitivity troponin T (hsTnT), a marker of CVD, and N-Terminal pro B-Type Natriuretic Peptide (NT-proBNP), a marker of heart failure, have not been widely studied in type 1 diabetes. We thus assessed the ability of these markers...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1618-P
Published: 01 July 2018
... disease, angina, stroke, or heart attack. Appropriate sample weights were used to provide a national estimate. Results of prevalence of CKD in U.S. adults with self-reported CVD are presented in Table 1. The prevalence of moderately to severely decreased renal impairment based on eGFR below 60 ml/min...
Meeting Abstracts
Journal: Diabetes
Diabetes 2021;70(Supplement_1):149-LB
Published: 01 June 2021
... is associated with greater degree of IR, inflammation and adverse CVD risk profile, independent of total body or truncal fat or evidence of fatty liver disease. This data suggest that higher FBG identifies obese Hispanic youth at high risk for CVD. Disclosure R. S. Shawar: None. M. R. Puyau: None...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):128-LB
Published: 01 June 2019
... endpoint of individualized HEDIS A1C targets at 6 months without severe and/or symptomatic documented hypoglycemia (blood glucose [BG] ≤70 mg/dL). Here we report outcomes in pts with and without CVD at baseline (BL). Characteristics at BL were generally well balanced between treatments, with a potential...
Meeting Abstracts
Journal: Diabetes
Diabetes 2019;68(Supplement_1):664-P
Published: 01 June 2019
...JODI KRALL; KRISTINE RUPPERT; ANA M. DIAZ; JESSICA FINNEY; LINDA M. SIMINERIO; INGRID LIBMAN Risk factors for CVD, the leading cause of premature death in adults with T1DM, are under-recognized and/or undertreated in youth with T1DM, suggesting a need for enhancing prevention and early self...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):698-P
Published: 01 July 2018
...JODI KRALL; INGRID LIBMAN; SAMINA AFREEN; LINDA M. SIMINERIO CVD is the leading cause of premature death in people with T1DM, yet many individuals are unaware. Strategies to engage youth in CVD prevention and lifelong disease management are needed. The purpose of this study was to gain insight from...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):15-LB
Published: 01 July 2018
..., without CVD at enrollment in the T1DX. CVD was defined as a composite outcome of clinic reported fatal or non-fatal events of ischemic heart disease and heart failure. Associations between diabetic specific and traditional CVD risk factors and incident CVD were examined by logistic regression adjusting...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):2381-PUB
Published: 01 July 2018
...TONGTONG WANG; YUZHI XI; ROBERT N. LUBWAMA; CAROL KORO Data on the prevalence of CKD among U.S. adults with T2D and CVD are limited. The aim of this study was to provide such estimates for T2D, both overall and in those with CVD. Using the NHANES 2007-2014 data, we conducted a cross-sectional...
Meeting Abstracts
Journal: Diabetes
Diabetes 2018;67(Supplement_1):1568-P
Published: 01 July 2018
...RACHEL G. MILLER; TREVOR J. ORCHARD CVD is a major contributor to T1D morbidity and mortality but presents in a variety of first manifestations. Thus we aimed to assess risk factors for 3 CVD manifestations in a T1D cohort: 1) major atherosclerotic cardiovascular event (MACE, i.e., CVD death...
Images
Algorithm for glucose-lowering medications in LADA patients with C-peptide ...
Published: 26 August 2020
Figure 2 Algorithm for glucose-lowering medications in LADA patients with C-peptide <0.3 mmol/L or with C-peptide ≥0.3 and ≤0.7 nmol/L. ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HF, heart ... More
Images
Schematic of bilirubin generation and conjugation in the liver. The physiol...
Published: 17 July 2014
Figure 1 Schematic of bilirubin generation and conjugation in the liver. The physiological properties of bilirubin may explain its ability to protect against the progression of DN. These properties make bilirubin a potential clinical biomarker or therapeutic target for a variety of disease states. BVR, biliverdin reductase; CAD, coronary artery disease; CO, carbon monoxide; CVD, cardiovascular disease; Fe2+, ferrous iron; Fe3+, ferric iron; NOS, nitric oxide synthase; RBC, erythrocyte; TNFα, tumor necrosis factor-α. Figure 1. Schematic of bilirubin generation and conjugation in the liver. The physiological properties of bilirubin may explain its ability to protect against the progression of DN. These properties make bilirubin a potential clinical biomarker or therapeutic target for a variety of disease states. BVR, biliverdin reductase; CAD, coronary artery disease; CO, carbon monoxide; CVD, cardiovascular disease; Fe2+, ferrous iron; Fe3+, ferric iron; NOS, nitric oxide synthase; RBC, erythrocyte; TNFα, tumor necrosis factor-α. More
Images
Serum PRO-C6 (marker of fibrosis) associated with kidney <span class="search-highlight">disease</span> progressio...
Published: 15 December 2020
Figure 4 Serum PRO-C6 (marker of fibrosis) associated with kidney disease progression (defined as a decline of eGFR of >30% from baseline) (A) and cardiovascular events (cardiovascular mortality, stroke, ischemic CVD, and heart failure) (B) in subjects with type 2 diabetes (n = 200) ( 60 ). Dotted line, tertile 1 (T1); dashed line, tertile 2 (T2); solid line, tertile 3 (T3). Figure 4. Serum PRO-C6 (marker of fibrosis) associated with kidney disease progression (defined as a decline of eGFR of >30% from baseline) (A) and cardiovascular events (cardiovascular mortality, stroke, ischemic CVD, and heart failure) (B) in subjects with type 2 diabetes (n = 200) (60). Dotted line, tertile 1 (T1); dashed line, tertile 2 (T2); solid line, tertile 3 (T3). More
Images
Impaired Nrf2 activation and antioxidant gene expression in fetal endotheli...
Published: 16 November 2013
FIG. 7. Impaired Nrf2 activation and antioxidant gene expression in fetal endothelial cells in GDM. The Nrf2-Keap1 antioxidant defense pathway is compromised in fetal endothelial cells exposed to maternal diabetes in utero, potentially as a consequence of decreased DJ-1 and increased p-GSK3β expre... More
Journal Articles
Journal: Diabetes
Diabetes 2021;70(1):1–16
Published: 26 October 2020
... is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed...
Journal Articles
Journal: Diabetes
Diabetes 2005;54(5):1607–1610
Published: 01 May 2005
... of APM1 gene (C-11365G, A-4034C, A-3964G, T45G, and G276T) with the risk of cardiovascular diseases (CVDs) in a larger cohort of diabetic patients. Of 879 diabetic men from the Health Professionals Follow-up Study, 239 participants developed coronary heart disease or stroke during 14 years of follow-up...
Includes: Supplementary data
Journal Articles
Journal: Diabetes
Diabetes 2006;55(5):1512–1516
Published: 01 May 2006
...) with circulating adiponectin levels and cardiovascular risk among women with type 2 diabetes. Of 989 diabetic women from the Nurses’ Health Study, 285 developed cardiovascular disease (CVD) during follow-up through 2000. We genotyped five ADIPOQ polymorphisms in the CVD case and control subjects...
Journal Articles
Journal: Diabetes
Diabetes 2005;54(12):3541–3546
Published: 01 December 2005
... cardiovascular disease (CVD) events among type 2 diabetic individuals, independent of metabolic syndrome features and other classical risk factors. We carried out a prospective nested case-control study in 2,103 type 2 diabetic patients who were free of diagnosed CVD at baseline. During 5 years of follow-up, 248...
Journal Articles
Journal: Diabetes
Diabetes 1992;41(Supplement_2):4–11
Published: 01 October 1992
... during the same time. In addition, a physical examination was performed on persons 45–74 yr old to measure the prevalence of cardiovascular and peripheral vascular diseases and known and suspected risk factors, in Phase II, CVD mortality and morbidity rates will be determined in the examined cohort...
Journal Articles
Journal: Diabetes
Diabetes 1994;43(3):426–429
Published: 01 March 1994
...Gabrieklla Gruden; Paolo Cavallo-Perin; Mario Bazzan; Stefania Stella; Antonio Vuolo; Gianfranco Pagano Microalbuminuria is associated with an increased risk of cardiovascular disease (CVD) in insulin-dependent diabetes mellitus (IDDM) patients, but the pathophysiological basis of this association...